AtriCure, Inc.

NasdaqGM:ATRC Rapporto sulle azioni

Cap. di mercato: US$1.2b

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

AtriCure Gestione

Gestione criteri di controllo 2/4

AtriCure's Il CEO è Mike Carrel, nominato in Nov2012, e ha un mandato di 11.75 anni. la retribuzione annua totale è $ 8.75M, composta da 9.2% di stipendio e 90.8% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 1.36% delle azioni della società, per un valore di $ 15.77M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 7.5 anni e 7.4 anni.

Informazioni chiave

Mike Carrel

Amministratore delegato

US$8.7m

Compenso totale

Percentuale dello stipendio del CEO9.2%
Mandato del CEO11.8yrs
Proprietà del CEO1.4%
Durata media del management7.5yrs
Durata media del Consiglio di amministrazione7.4yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analysts Have Been Trimming Their AtriCure, Inc. (NASDAQ:ATRC) Price Target After Its Latest Report

Aug 02
Analysts Have Been Trimming Their AtriCure, Inc. (NASDAQ:ATRC) Price Target After Its Latest Report

AtriCure's Latest Projects And European Market Entry, Advancing Cardiac Care

Jul 25

AtriCure, Inc. (NASDAQ:ATRC) Soars 26% But It's A Story Of Risk Vs Reward

Jul 18
AtriCure, Inc. (NASDAQ:ATRC) Soars 26% But It's A Story Of Risk Vs Reward

AtriCure, Inc.'s (NASDAQ:ATRC) Intrinsic Value Is Potentially 88% Above Its Share Price

May 30
AtriCure, Inc.'s (NASDAQ:ATRC) Intrinsic Value Is Potentially 88% Above Its Share Price

Positive Sentiment Still Eludes AtriCure, Inc. (NASDAQ:ATRC) Following 29% Share Price Slump

Apr 04
Positive Sentiment Still Eludes AtriCure, Inc. (NASDAQ:ATRC) Following 29% Share Price Slump

Does AtriCure (NASDAQ:ATRC) Have A Healthy Balance Sheet?

Mar 14
Does AtriCure (NASDAQ:ATRC) Have A Healthy Balance Sheet?

Investors Interested In AtriCure, Inc.'s (NASDAQ:ATRC) Revenues

Jan 21
Investors Interested In AtriCure, Inc.'s (NASDAQ:ATRC) Revenues

Is AtriCure (NASDAQ:ATRC) Using Debt In A Risky Way?

Nov 29
Is AtriCure (NASDAQ:ATRC) Using Debt In A Risky Way?

AtriCure, Inc.'s (NASDAQ:ATRC) Intrinsic Value Is Potentially 99% Above Its Share Price

Sep 27
AtriCure, Inc.'s (NASDAQ:ATRC) Intrinsic Value Is Potentially 99% Above Its Share Price

Health Check: How Prudently Does AtriCure (NASDAQ:ATRC) Use Debt?

Aug 02
Health Check: How Prudently Does AtriCure (NASDAQ:ATRC) Use Debt?

AtriCure, Inc.'s (NASDAQ:ATRC) Share Price Matching Investor Opinion

Jun 15
AtriCure, Inc.'s (NASDAQ:ATRC) Share Price Matching Investor Opinion

Is AtriCure (NASDAQ:ATRC) Weighed On By Its Debt Load?

Apr 14
Is AtriCure (NASDAQ:ATRC) Weighed On By Its Debt Load?

Calculating The Intrinsic Value Of AtriCure, Inc. (NASDAQ:ATRC)

Mar 02
Calculating The Intrinsic Value Of AtriCure, Inc. (NASDAQ:ATRC)

What Does AtriCure, Inc.'s (NASDAQ:ATRC) Share Price Indicate?

Feb 09
What Does AtriCure, Inc.'s (NASDAQ:ATRC) Share Price Indicate?

Is AtriCure (NASDAQ:ATRC) Using Debt In A Risky Way?

Dec 28
Is AtriCure (NASDAQ:ATRC) Using Debt In A Risky Way?

Is Now An Opportune Moment To Examine AtriCure, Inc. (NASDAQ:ATRC)?

Sep 06
Is Now An Opportune Moment To Examine AtriCure, Inc. (NASDAQ:ATRC)?

An Intrinsic Calculation For AtriCure, Inc. (NASDAQ:ATRC) Suggests It's 29% Undervalued

Aug 02
An Intrinsic Calculation For AtriCure, Inc. (NASDAQ:ATRC) Suggests It's 29% Undervalued

AtriCure: 5x Sales For A Series Of Impeding Losses? No Thanks

Jun 13

Is AtriCure (NASDAQ:ATRC) Weighed On By Its Debt Load?

Jun 08
Is AtriCure (NASDAQ:ATRC) Weighed On By Its Debt Load?

Is It Time To Consider Buying AtriCure, Inc. (NASDAQ:ATRC)?

May 08
Is It Time To Consider Buying AtriCure, Inc. (NASDAQ:ATRC)?

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Mike Carrel rispetto agli utili di AtriCure?
DataCompenso totaleStipendioGuadagni aziendali
Jun 30 2024n/an/a

-US$40m

Mar 31 2024n/an/a

-US$37m

Dec 31 2023US$9mUS$804k

-US$30m

Sep 30 2023n/an/a

-US$25m

Jun 30 2023n/an/a

-US$28m

Mar 31 2023n/an/a

-US$38m

Dec 31 2022US$8mUS$795k

-US$46m

Sep 30 2022n/an/a

-US$56m

Jun 30 2022n/an/a

US$53m

Mar 31 2022n/an/a

US$52m

Dec 31 2021US$8mUS$766k

US$50m

Sep 30 2021n/an/a

US$45m

Jun 30 2021n/an/a

-US$57m

Mar 31 2021n/an/a

-US$49m

Dec 31 2020US$6mUS$718k

-US$48m

Sep 30 2020n/an/a

-US$46m

Jun 30 2020n/an/a

-US$50m

Mar 31 2020n/an/a

-US$46m

Dec 31 2019US$6mUS$740k

-US$35m

Sep 30 2019n/an/a

-US$23m

Jun 30 2019n/an/a

-US$20m

Mar 31 2019n/an/a

-US$17m

Dec 31 2018US$4mUS$714k

-US$21m

Sep 30 2018n/an/a

-US$20m

Jun 30 2018n/an/a

-US$20m

Mar 31 2018n/an/a

-US$27m

Dec 31 2017US$4mUS$671k

-US$27m

Compensazione vs Mercato: La retribuzione totale di Mike ($USD 8.75M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 3.30M ).

Compensazione vs guadagni: La retribuzione di Mike è aumentata nonostante l'azienda non sia redditizia.


AMMINISTRATORE DELEGATO

Mike Carrel (53 yo)

11.8yrs

Mandato

US$8,749,289

Compensazione

Mr. Michael H. Carrel, also known as Mike, serves as the Chief Executive Officer and President at AtriCure, Inc. since November 2012. Mr. Carrel has been Director at Axonics Inc. since February 27, 2019 an...


Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Michael Carrel
CEO, President & Director11.8yrsUS$8.75m1.36%
$ 15.8m
Angela Wirick
Chief Financial Officer4yrsUS$2.92m0.29%
$ 3.3m
Douglas Seith
Chief Operating Officer9.6yrsUS$3.50m0.32%
$ 3.7m
Salvatore Privitera
Chief Technical Officer7.6yrsUS$2.13m0.21%
$ 2.5m
Karl Dahlquist
Chief Legal Officer5.4yrsUS$2.13m0.11%
$ 1.2m
Vinayak Doraiswamy
Chief Scientific Officer7.4yrsUS$1.78m0.12%
$ 1.4m
Valerie Storch-Willhaus
Vice President of Corporate Marketing & Communicationsno dataNessun datoNessun dato
Justin Noznesky
Chief Marketing & Strategy Officer8.4yrsUS$1.78m0.15%
$ 1.7m
Deborah Yount
Chief Human Resources Officer2.2yrsUS$1.92m0.098%
$ 1.1m

7.5yrs

Durata media

53yo

Età media

Gestione esperta: Il team dirigenziale di ATRC è esperto e expertise (durata media dell'incarico 7.5 anni).


Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Michael Carrel
CEO, President & Director11.8yrsUS$8.75m1.36%
$ 15.8m
Sven Wehrwein
Independent Director7.8yrsUS$227.47k0.059%
$ 691.6k
B. Johnson
Independent Director7.4yrsUS$264.97k0.091%
$ 1.1m
Shlomi Nachman
Independent Directorless than a yearNessun dato0.027%
$ 312.9k
Robert White
Independent Chairman of the Board11.4yrsUS$225.47k0.20%
$ 2.3m
Karen Prange
Independent Director4.7yrsUS$219.97k0.049%
$ 571.2k
Maggie Yuen
Independent Director3.2yrsUS$209.97k0.026%
$ 297.7k
Regina Groves
Independent Director7.4yrsUS$232.47k0.063%
$ 734.4k
Deborah Telman
Independent Director3.2yrsUS$212.47k0.034%
$ 400.6k

7.4yrs

Durata media

62yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di ATRC sono considerati esperti (durata media dell'incarico 7.4 anni).